Namcold DX

Namcold DX is an extended-release oral suspension developed by Lincoln Pharmaceuticals Ltd for the treatment of cough and cold symptoms. Launched in 2015, the product is categorized as a New Drug Delivery System (NDDS) innovation, providing a sustained-release liquid formulation of existing active ingredients. While marketing materials often emphasize the delivery technology, the 'DX' designation in the Indian pharmaceutical market typically indicates a combination of the antitussive dextromethorphan and the antihistamine chlorpheniramine. The formulation is designed to provide long-lasting relief from non-productive cough and allergic symptoms associated with the common cold. Lincoln Pharmaceuticals distributes the product domestically in India and exports it to numerous international markets.

Brand names

Namcold DX

Other names

Namcold DX Oral Suspension